
    
      This is a prospective, single-center and single-arm exploratory clinical study designed to
      evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of
      patients with BCLC stage B and C hepatocellular carcinoma.Treatment will continue until
      disease progression or intolerable toxicity or patients withdrawal of consent,and the target
      sample size is 60 individuals.
    
  